Making The Case For A Legislative Deal On Drug Pricing

Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing ‘behind us’ with a legislative compromise.

Jim Greenwood has a good feeling about door number two.

More from Pricing Debate

More from Market Access